Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research

On behalf of the EFSA WG EPI1 and its other members

Research output: Contribution to journalReview article

Abstract

Infant leukaemia (<1 year old) is a rare disease of an in utero origin at an early phase of foetal development. Rearrangements of the mixed-lineage leukaemia (MLL) gene producing abnormal fusion proteins are the most frequent genetic/molecular findings in infant B cell-acute lymphoblastic leukaemia. In small epidemiological studies, mother/foetus exposures to some chemicals including pesticides have been associated with infant leukaemia; however, the strength of evidence and power of these studies are weak at best. Experimental in vitro or in vivo models do not sufficiently recapitulate the human disease and regulatory toxicology studies are unlikely to capture this kind of hazard. Here, we develop an adverse outcome pathway (AOP) based substantially on an analogous disease—secondary acute leukaemia caused by the topoisomerase II (topo II) poison etoposide—and on cellular and animal models. The hallmark of the AOP is the formation of MLL gene rearrangements via topo II poisoning, leading to fusion genes and ultimately acute leukaemia by global (epi)genetic dysregulation. The AOP condenses molecular, pathological, regulatory and clinical knowledge in a pragmatic, transparent and weight of evidence-based framework. This facilitates the interpretation and integration of epidemiological studies in the process of risk assessment by defining the biologically plausible causative mechanism(s). The AOP identified important gaps in the knowledge relevant to aetiology and risk assessment, including the specific embryonic target cell during the short and spatially restricted period of susceptibility, and the role of (epi)genetic features modifying the initiation and progression of the disease. Furthermore, the suggested AOP informs on a potential Integrated Approach to Testing and Assessment to address the risk caused by environmental chemicals in the future.

Original languageEnglish
Pages (from-to)2763-2780
Number of pages18
JournalArchives of Toxicology
Volume91
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Child Development
Risk assessment
Type II DNA Topoisomerase
Leukemia
Genes
Fusion reactions
Research
Poisons
Pesticides
Epidemiologic Studies
Hazards
Animals
Cells
Process Assessment (Health Care)
Gene Rearrangement
Gene Fusion
Testing
Rare Diseases
Fetal Development
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

  • DNA topoisomerase II
  • Etoposide
  • Infant leukaemia
  • MLL fusion products
  • Risk assessment

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Chemical exposure and infant leukaemia : development of an adverse outcome pathway (AOP) for aetiology and risk assessment research. / On behalf of the EFSA WG EPI1 and its other members.

In: Archives of Toxicology, Vol. 91, No. 8, 01.08.2017, p. 2763-2780.

Research output: Contribution to journalReview article

@article{9dd2c22a0fb5451c9d175ff451d175c9,
title = "Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research",
abstract = "Infant leukaemia (<1 year old) is a rare disease of an in utero origin at an early phase of foetal development. Rearrangements of the mixed-lineage leukaemia (MLL) gene producing abnormal fusion proteins are the most frequent genetic/molecular findings in infant B cell-acute lymphoblastic leukaemia. In small epidemiological studies, mother/foetus exposures to some chemicals including pesticides have been associated with infant leukaemia; however, the strength of evidence and power of these studies are weak at best. Experimental in vitro or in vivo models do not sufficiently recapitulate the human disease and regulatory toxicology studies are unlikely to capture this kind of hazard. Here, we develop an adverse outcome pathway (AOP) based substantially on an analogous disease—secondary acute leukaemia caused by the topoisomerase II (topo II) poison etoposide—and on cellular and animal models. The hallmark of the AOP is the formation of MLL gene rearrangements via topo II poisoning, leading to fusion genes and ultimately acute leukaemia by global (epi)genetic dysregulation. The AOP condenses molecular, pathological, regulatory and clinical knowledge in a pragmatic, transparent and weight of evidence-based framework. This facilitates the interpretation and integration of epidemiological studies in the process of risk assessment by defining the biologically plausible causative mechanism(s). The AOP identified important gaps in the knowledge relevant to aetiology and risk assessment, including the specific embryonic target cell during the short and spatially restricted period of susceptibility, and the role of (epi)genetic features modifying the initiation and progression of the disease. Furthermore, the suggested AOP informs on a potential Integrated Approach to Testing and Assessment to address the risk caused by environmental chemicals in the future.",
keywords = "DNA topoisomerase II, Etoposide, Infant leukaemia, MLL fusion products, Risk assessment",
author = "{On behalf of the EFSA WG EPI1 and its other members} and Olavi Pelkonen and Andrea Terron and Hernandez, {Antonio F.} and Pablo Menendez and Bennekou, {Susanne Hougaard} and Karine Angeli and Ellen Fritsche and Marcel Leist and Alberto Mantovani and Anna Price and Barbara Viviani",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s00204-017-1986-x",
language = "English",
volume = "91",
pages = "2763--2780",
journal = "Archiv fur Toxikologie",
issn = "0003-9446",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Chemical exposure and infant leukaemia

T2 - development of an adverse outcome pathway (AOP) for aetiology and risk assessment research

AU - On behalf of the EFSA WG EPI1 and its other members

AU - Pelkonen, Olavi

AU - Terron, Andrea

AU - Hernandez, Antonio F.

AU - Menendez, Pablo

AU - Bennekou, Susanne Hougaard

AU - Angeli, Karine

AU - Fritsche, Ellen

AU - Leist, Marcel

AU - Mantovani, Alberto

AU - Price, Anna

AU - Viviani, Barbara

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Infant leukaemia (<1 year old) is a rare disease of an in utero origin at an early phase of foetal development. Rearrangements of the mixed-lineage leukaemia (MLL) gene producing abnormal fusion proteins are the most frequent genetic/molecular findings in infant B cell-acute lymphoblastic leukaemia. In small epidemiological studies, mother/foetus exposures to some chemicals including pesticides have been associated with infant leukaemia; however, the strength of evidence and power of these studies are weak at best. Experimental in vitro or in vivo models do not sufficiently recapitulate the human disease and regulatory toxicology studies are unlikely to capture this kind of hazard. Here, we develop an adverse outcome pathway (AOP) based substantially on an analogous disease—secondary acute leukaemia caused by the topoisomerase II (topo II) poison etoposide—and on cellular and animal models. The hallmark of the AOP is the formation of MLL gene rearrangements via topo II poisoning, leading to fusion genes and ultimately acute leukaemia by global (epi)genetic dysregulation. The AOP condenses molecular, pathological, regulatory and clinical knowledge in a pragmatic, transparent and weight of evidence-based framework. This facilitates the interpretation and integration of epidemiological studies in the process of risk assessment by defining the biologically plausible causative mechanism(s). The AOP identified important gaps in the knowledge relevant to aetiology and risk assessment, including the specific embryonic target cell during the short and spatially restricted period of susceptibility, and the role of (epi)genetic features modifying the initiation and progression of the disease. Furthermore, the suggested AOP informs on a potential Integrated Approach to Testing and Assessment to address the risk caused by environmental chemicals in the future.

AB - Infant leukaemia (<1 year old) is a rare disease of an in utero origin at an early phase of foetal development. Rearrangements of the mixed-lineage leukaemia (MLL) gene producing abnormal fusion proteins are the most frequent genetic/molecular findings in infant B cell-acute lymphoblastic leukaemia. In small epidemiological studies, mother/foetus exposures to some chemicals including pesticides have been associated with infant leukaemia; however, the strength of evidence and power of these studies are weak at best. Experimental in vitro or in vivo models do not sufficiently recapitulate the human disease and regulatory toxicology studies are unlikely to capture this kind of hazard. Here, we develop an adverse outcome pathway (AOP) based substantially on an analogous disease—secondary acute leukaemia caused by the topoisomerase II (topo II) poison etoposide—and on cellular and animal models. The hallmark of the AOP is the formation of MLL gene rearrangements via topo II poisoning, leading to fusion genes and ultimately acute leukaemia by global (epi)genetic dysregulation. The AOP condenses molecular, pathological, regulatory and clinical knowledge in a pragmatic, transparent and weight of evidence-based framework. This facilitates the interpretation and integration of epidemiological studies in the process of risk assessment by defining the biologically plausible causative mechanism(s). The AOP identified important gaps in the knowledge relevant to aetiology and risk assessment, including the specific embryonic target cell during the short and spatially restricted period of susceptibility, and the role of (epi)genetic features modifying the initiation and progression of the disease. Furthermore, the suggested AOP informs on a potential Integrated Approach to Testing and Assessment to address the risk caused by environmental chemicals in the future.

KW - DNA topoisomerase II

KW - Etoposide

KW - Infant leukaemia

KW - MLL fusion products

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=85019958919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019958919&partnerID=8YFLogxK

U2 - 10.1007/s00204-017-1986-x

DO - 10.1007/s00204-017-1986-x

M3 - Review article

AN - SCOPUS:85019958919

VL - 91

SP - 2763

EP - 2780

JO - Archiv fur Toxikologie

JF - Archiv fur Toxikologie

SN - 0003-9446

IS - 8

ER -